Great Lakes Clinical Trial staff, under the direction of Medical Director, Jeffrey Ross, MD, are pleased to share the results of Alder Biopharmaceuticals' migraine research program which were released earlier today. A press release has been issued entitled,
Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints in Pivotal PROMISE 2 Phase 3 Trial for Chronic Migraine Prevention
The highlights of the press release include:
- Highly statistically significant results with rapid prevention beginning Day One
- 50%, 75%, 100% responder rates by month one sustained for three months
- 15% of patients had no migraines for a full three months
To view a full copy of the press release click HERE.
"Our clinic is an independent and unbiased research facility for the testing of investigational medicals for a variety of diseases, including migraines. Our primary service is for our medical staff to work closely with our patients and determine if a new medication works or not, and assess its safety." commented Steve Satek, Great Lakes Clinical Trials President. "When we hear positive results from research programs which we conducted on such as this Alder Biopharmaceuticals migraine program, it reaffirms our company's mission to advance the science of medicine and improve the quality of life and health of patients around the world.
All services at Great Lakes Clinical Trials are provided at no cost and are conducted by board-certified physicians. No insurance required. For a full listing of studies currently being conducted at Great Lakes Clinical Trials, visit our Studies page by clicking here.